Healius 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Paul Anderson

최고 경영자

AU$944.6k

총 보상

CEO 급여 비율	97.7%
CEO 임기	less than a year
CEO 소유권	n/a
경영진 평균 재임 기간	1.6yrs
이사회 평균 재임 기간	2.7yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Paul Anderson 의 보수는 Healius 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	AU$945k	AU$923k	-AU$636m
Dec 31 2023	n/a	n/a	-AU$984m
Sep 30 2023	n/a	n/a	-AU$682m
Jun 30 2023	AU$235k	AU$194k	-AU$380m

보상 대 시장: Paul 의 총 보상 ($USD 609.87K ) Australian 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 1.08M ).

보상과 수익: 회사가 수익성이 없는 동안 Paul 의 보상이 증가했습니다.

CEO

Paul Anderson

less than a year

테뉴어

AU$944,623

보상

Mr. Paul D. Anderson, B COMM, CA serves as Managing Director, Chief Executive Officer since 2024 at Healius Limited and had been Group Chief Financial Officer of Healius Limited since March 1, 2023 and als...

리더십 팀

이름	위치	테뉴어	보상	소유권
Paul Anderson	MD, CEO & Director	less than a year	AU$944.62k	데이터 없음
Stephen Humphries	CFO& Company Secretary	1.7yrs	AU$718.57k	0.0024% A$ 23.0k
Jan Van Rooyen	Head & Group Executive of Healius Pathology	1.4yrs	AU$1.43m	데이터 없음
Paula Bayliss	Group Executive of People & Culture	less than a year	데이터 없음	데이터 없음
John McKechnie	Advisor	5.3yrs	AU$275.71k	0% A$ 0
Phil Lucas	Chief Executive of Lumus Imaging	1.8yrs	데이터 없음	데이터 없음
Ian Mcphan	Chief Operating Officer of Healius Pathology	no data	데이터 없음	데이터 없음
Sharon Ng	Head of Group FP&A	no data	데이터 없음	데이터 없음
Arjun Narang	Group Executive of Operations Transformation	1.5yrs	데이터 없음	데이터 없음
Jon Eide	Group Executive of Commercial & Customer	1.6yrs	데이터 없음	데이터 없음
Alejandro Rosales	Head of Digital Strategy & Delivery Office	no data	데이터 없음	데이터 없음
Mary Weaver	Company Secretary	1.7yrs	데이터 없음	데이터 없음

1.6yrs

평균 재임 기간

경험이 풍부한 관리: HLS 의 관리팀은 경험 (평균 재직 기간 1.6 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Paul Anderson	MD, CEO & Director	less than a year	AU$944.62k	데이터 없음
Gordon Davis	Non-Executive Director	9.3yrs	AU$180.18k	0.017% A$ 163.2k
Kathryn McKenzie	Interim Non-Executive Independent Chair	3.8yrs	AU$269.98k	0.014% A$ 133.7k
Michael Stanford	Independent Non-Executive Director	1.2yrs	AU$138.74k	0.0045% A$ 43.3k
Sally Evans	Independent Non-Executive Director	6.3yrs	AU$185.00k	0.013% A$ 128.7k
John Mattick	Non Executive & Independent Director	2.7yrs	AU$170.00k	0.0075% A$ 72.5k
Charlie Taylor	Independent Non-Executive Director	1.7yrs	AU$174.82k	0.018% A$ 177.4k

2.7yrs

평균 재임 기간

65yo

평균 연령

경험이 풍부한 이사회: HLS 의 이사회는 경험(평균 재직 기간 2.7 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Healius 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Healius Limited, Annual General Meeting, Nov 15, 2024

Healius Limited Announces Step Down of Ravi Jeyaraj as Non-Executive Director, Effective 2 August 2024

High number of new directors

Interim Non-Executive Independent Chair recently bought AU$81k worth of stock

High number of new directors

Healius Limited Appoints Ravi Jeyaraj as Director

Recent updates

Affinity Equity Partners (Australia) Pty Limited entered into a binding agreement to acquire Lumus Imaging from Healius Limited (ASX:HLS) for enterprise value of AUD 965 million.

Full year 2024 earnings released: AU$0.96 loss per share (vs AU$0.67 loss in FY 2023)

Healius Limited, Annual General Meeting, Nov 15, 2024

Full year 2024 earnings released

TPG Capital, PEP Reportedly Still Competing for Healius Lumus Imaging

Final Bids Reportedly Expected for Healius

Healius Limited Announces Step Down of Ravi Jeyaraj as Non-Executive Director, Effective 2 August 2024

Macquarie Unit Reportedly in Healius Race

Healius Limited to Report Fiscal Year 2024 Results on Aug 21, 2024

Sonic in the Running for Healius Imaging Business

Private Equity Reportedly Eyes Healius Diagnostic Imaging Unit

High number of new directors

Healius Limited to Report First Half, 2024 Results on Feb 27, 2024

Australian Clinical Labs Limited (ASX:ACL) cancelled the acquisition of Healius Limited (ASX:HLS) from Tanarra Capital Australia Pty Ltd, Perpetual Investment Management Ltd and others.

New minor risk - Shareholder dilution

Interim Non-Executive Independent Chair recently bought AU$81k worth of stock

High number of new directors

Healius Limited Appoints Ravi Jeyaraj as Director

Healius Limited Announces Chair Changes

Healius Limited Announces Chair Changes

Healius Limited has filed a Follow-on Equity Offering in the amount of AUD 187.32 million.

Healius Limited has filed a Follow-on Equity Offering in the amount of AUD 187.32 million.

Healius Limited, Annual General Meeting, Nov 01, 2023

Australian Clinical Labs Limited (ASX:ACL) canceled the acquisition of Healius Limited (ASX:HLS)

Healius Limited Appoints Michael Stanford as Director

Full year 2023 earnings released

Healius Limited to Report Fiscal Year 2023 Results on Aug 30, 2023

Healius Limited Appoints Jan Van Rooyen as Group Executive, Healius Pathology Effective 1 June 2023

High number of new directors

Independent Non Executive Chairman recently bought AU$103k worth of stock

First half 2023 earnings released: AU$0.045 loss per share (vs AU$0.40 profit in 1H 2022)

Healius Limited Announces Resignation of Alison Stephenson as Company Secretary

Healius Limited to Report First Half, 2023 Results on Feb 27, 2023

Nexus Hospitals entered into an agreement to acquire Montserrat Healthcare Pty Ltd from Healius Limited (ASX:HLS).

QIC Reportedly Set to Clinch Healius Day Hospital Unit for $140 Million Plus

MD, CEO & Director recently sold AU$660k worth of stock

Brookfield Reportedly Drops Out of Race to Buy Healius

Independent Non Executive Director recently bought AU$86k worth of stock

Non Executive & Independent Director recently bought AU$70k worth of stock

Full year 2022 earnings released: EPS: AU$0.50 (vs AU$0.11 in FY 2021)

Healius Limited Announces Fully Franked Ordinary Paid Dividend for the Six Months Ended June 30, 2022, Payable on September 21, 2022

Healius Limited, Annual General Meeting, Oct 20, 2022

Healius Reportedly Launches Day Surgery Sale Process

Healius Reportedly Keeps Watching Brief on Integral Diagnostics

Healius Limited to Report Fiscal Year 2022 Results on Aug 31, 2022

Healius Reportedly Seeks X-Ray Factor in Day Surgeries Sale Plan

Healius Limited Announces Appointment of John Mattick as Non-Executive Director

Upcoming dividend of AU$0.10 per share

First half 2022 earnings: EPS in line with expectations, revenues disappoint

Healius Limited Announces Ordinary Fully Paid Dividend for the Period of Six Months December 31, 2021, Payable April 15, 2022

Healius Limited to Report First Half, 2022 Results on Feb 23, 2022

Healius Limited (ASX:HLS) acquired Agilex Biolabs Pty Ltd.

Healius Limited (ASX:HLS) entered into an agreement to acquire Agilex Biolabs Pty Ltd for approximately AUD 300 million.

MD, CEO & Director recently sold AU$713k worth of stock

Upcoming dividend of AU$0.068 per share

Full year 2021 earnings released: EPS AU$0.11 (vs AU$0.12 in FY 2020)

Healius Limited (ASX:HLS) acquired Axis Diagnostic Holdings Pty Limited.

Healius Reportedly to Sale Day Surgeries

Healius Limited Decides Not to Provide Earnings Guidance for the Second Half of 2021

Healius Limited Appoints Kate McKenzie as A Non-Executive Director Effective from 25 February 2021

New 90-day high: AU$4.16

Healius Limited(ASX:HLS) dropped from S&P/ASX 100 Index

New 90-day high: AU$3.90

BGH Capital completed the acqusition of Primary Care Business of Healius Ltd from Healius Limited (ASX:HLS) for AUD485 million.

Independent Non Executive Director recently bought AU$53k worth of stock

New 90-day high: AU$3.77

Healius Limited Announces Retirement of Arlene Tansey as Non-Executive Director

New 90-day high: AU$3.46

Healius Limited to Report Fiscal Year 2021 Results on Aug 20, 2021